 20 February 2012 Starpharma Interim Report and Half-year Financial ResultsStarpharma Holdings today released its interim report and financial results for the half-year ended 31 December 2011. Financial Results
|
 1 February 2012 Starpharma’s dendrimers improve efficacy of docetaxel in animals- Starpharma's dendrimer-docetaxel formulation significantly more effective than leading cancer drug docetaxel (Taxotere®) in breast cancer model - More than half (60%) of animals treated with Starpharma's dendrimer-docetaxel formulation had no evidence of tumour at 94 days whereas with docetaxel significant tumour regrowth was observed in all animals - Starpharma's dendrimer-docetaxel formulation improved water solubility by 5000-fold Read more |
 11 January 2012 SPL receives FDA Special Protocol Assessment for BV Phase 3Starpharma today announced that it has received final written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme. The SPA is a binding declaration from the FDA that the Phase 3 clinical study design, endpoints, statistical analyses, and other aspects of the planned studies are acceptable to support regulatory approval of the product. Read more |
 19 December 2011 Starpharma's drug delivery program with Lilly advancesStarpharma today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company. Read more |
 14 February 2012 Herald Sun: In the BlackHerald Sun Journalist John Beveridge details how biotechnology companies are working to ‘fix many ailments’, with specific reference to promising results emerging from Starpharma’s diverse research portfolio. The best thing about Starpharma is that it owns a genuine platform technology that is capable of spinning off multiple products across a range of different and highly lucrative areas. It owns a forest of patents on dendrimers—tiny polymers which can be engineered to create many different results, such as making a drug water soluble or preventing the transmission of viruses and bacteria. Chief executive Dr Jackie Fairley said the recent approval from the US Food and Drug Administration and European regulators for phase 3 trials of its VivaGel product later this year was a highly significant step in bringing the product to market. |
 10 February 2012 Bioshares Report: Starpharma Takes Aim at DocetaxelThis Bioshares analysis provides insight into promising advancements within the Biotech sector in 2012. Starpharma is recognised for achieving a significant rise in shareprice and reaching exciting milestones in the development and pending commercialisation of its diverse research portfolio.
Download: Bioshares Issue 442 (pdf file, 27kb) |
 8 February 2012 Australian Financial Review: Biotechs making a steady recoveryAustralian Financial Review Journalist Brendon Lau investigates how Australian biotech companies are attracting the attention of local and international investors. There is likely to be a sharp pick-up in interest in Australian biotechs this year as they move into their next phase of growth, which will pave the way for them to be taken over by global drug companies. Most of the capital is expected to be invested in the Australian market as our biotech sector is considered to be the most mature in the region following the resounding success of the likes of Mesoblast, Acrux and Starpharma Holdings, which have put Australia on the global biotech stage. Retail shareholders strongly oversubscribed for their entitlements at recent capital raisings by Alchemia, Phosphagenics and Starpharma – the latter two attracting new overseas professional and high net-worth investors. |
12 January 2012 Australian Financial Review: Starpharma's VivaGel step closer to marketAustralian Financial Review Journalist Carrie LaFrenz reports: Emerging biotech Starpharma Holdings has been given the tick of approval from the US Federal and Drug Administration on the design of its Phase 3 clinical studies for its key VivaGel product, taking it one step closer to market. Starpharma has a number of promising technologies and has caught the attention of some large investors. UK-based M&G Investments took a 6.7 per cent stake following the successful $32 million placement in November. |
 20 December 2011 Shareholder Update: December 2011In this issue: › Starpharma raises $35m to advance pipeline › Starpharma signs with Ansell for condom coating › Putting a stop to stubborn BV: The VivaGel© solution › Clinical trials for VivaGel© gather pace › M&G invests $20 million › Dendrimers through the eyes of Professor Donald Tomalia
Download: Shareholder Update: December 2011 (pdf file, 628kb) Read more |
 26 July 2011 Shareholder Update: July 2011In this issue: › VivaGel® demonstrates efficacy in the treatment of bacterial vaginosis; Independent study finds link between bacterial vaginosis and HIV › Japanese VivaGel® condom deal secures second largest condom market in the world › Starpharma’s Priostar dendrimers improve bestselling herbicide › Drug delivery program delivers early-stage results in improving blockbuster chemo drug.
Download: Shareholder Update: July 2011 ( pdf file, 1MB) Read more |